RE: Conference Call.......no new News
Polak......thanks, however it is no secret that NN was negotiating for the INT Exclusive or expanded agreement. It is also no secret that Dr. Cruz and Co. will NOT let it go for a song. This may not have been universally known (as shown by the ignorance displayed on this BB), but anyone that did their DD would have known this since the first week of July. I for one support their decision to throw caution to the wind and hold out for an agreement that has Performance Guarantees with a roadmap to commercialize EVERY aspect of the INT Platform including E1-INT (E1+TT-223) that NN had. Even E1-INT for Transplantation will be useful in the fight against diabetes when used to enhance the 'Edmonton Protocol' based Transplants. NN never did have E1+TT-223 for Transplantation and there are studys being done from grants from the JDRF supporting this initiative.
Transition believes that E1+TT-223 will be good for dosing for every 6 months or more and that GLP1/TT223 will be a more Chronic Dosing (perhaps bi-weekly at least or monthly up to bi-monthly). Recall Byetta is twice daily and Liraglutide will be once daily if approved......and that Byetta LAR is looking at once weekly.(thats how far behind NN is in the incretin mimetic game!)
I am surprised that Dr. Cruz didn't mention that these 2 Dose Range Expansion Studys that started in Sept. were requested by any certain parties......BUT that is probably at the request of the interested parties to stay anonymous during negotiations. A couple of Analysts believe this to be the story as well.
I for one am actually glad NN didn't get the expanded agreement. I think its excellent that INT (tm) is now unencumbered and we can get on with business.
As far as the Drug Discovery Program they ARE moving Lead Molecules into pre-clinicals presently but will NOT divulge any info until successful and Patents applied for. Recall the New Hire in Transitions Clinic. Until such time they will remain trade secrets.....but it is moving forward and Dr. Cruz is on the record in August as saying that 2 Lead Molecules targeting Cardiovascular Disease will more than likely get the nod to go first. But because they have a backlog of 6 or 7 Lead Molecules, that target may have already been tested and dropped and the next one moved on to.....but I doubt it.
GPP all.......and good luck.